左手原料右手技术，推动胶原蛋白创新应用

Group 1 - Jiangsu Bochuang Biotechnology Co., Ltd. has initiated a clinical study for its collagen artificial cornea, marking a significant advancement in its research and development efforts [1] - The company has successfully mass-produced high-purity and high-activity collagen since its establishment in June 2022, and has developed products such as artificial cornea matrix sheets and oral bone tissue guiding membranes [1][5] - Bochuang Biotechnology has completed three rounds of financing within three and a half years and has been recognized as a high-tech enterprise and a "Star of Scientific Innovation" [1] Group 2 - The core technology of Bochuang Biotechnology is based on the research team led by Academician Liu Changsheng and Professor Qu Xue from East China University of Science and Technology, focusing on controllable electrochemical assembly (EDP) technology [2] - EDP technology allows for the precise control of collagen molecular assembly, significantly improving the structural integrity and functionality of biological tissue functional membranes [2][3] - The efficiency of membrane production using EDP technology is over ten times that of traditional methods, and it operates without toxic solvents, ensuring safety and reliability [3] Group 3 - The company has developed a unique oral bone tissue guiding membrane that promotes osteogenic cell growth while preventing other cells from entering the bone defect area, enhancing healing [3] - The artificial cornea developed by the company achieves over 95% light transmittance by controlling the arrangement of collagen molecules [3] - Bochuang Biotechnology aims to leverage its technology to transition innovations from laboratory settings to practical medical applications, benefiting more patients [3] Group 4 - The company has established a 1,400 square meter research facility and a 2,100 square meter GMP cleanroom within a year, demonstrating rapid development capabilities [4] - Recent angel round financing has played a crucial role in accelerating product development, with the company securing several million yuan in Pre-A round financing [4] - The successful communication of the company's core technological advantages and clinical value has attracted significant investment, validating its business model [4] Group 5 - Initially sourcing high-quality collagen from Japan, the company has successfully developed its own I-type high-activity collagen raw material with over 99% purity, reducing risks associated with immune response and viral contamination [5] - The company’s medical-grade high-purity collagen is now produced in bulk, providing raw materials for its own products and supplying other medical device companies for collaborative development [6] Group 6 - Bochuang Biotechnology is positioned in a market characterized by both international giants and domestic enterprises, focusing on the innovative application of biological materials in the medical field [7] - The company has applied for 15 patents, with 10 granted, emphasizing its commitment to building a technological moat in the competitive landscape [7] - Collaboration with East China University of Science and Technology has led to the establishment of a joint laboratory focused on ophthalmic biomaterials, promoting technological advancement and industrialization [7] Group 7 - The company aims to address market demands in alveolar bone repair and corneal repair, expanding its applications in various clinical settings [8] - By focusing on both raw materials and technology, Bochuang Biotechnology is positioned for rapid growth and innovation in the medical materials sector [7][8]